Developing a programmable siRNA-based therapeutic platform for gene silencing in the skin
开发基于 siRNA 的可编程治疗平台,用于皮肤基因沉默
基本信息
- 批准号:10723917
- 负责人:
- 金额:$ 11.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcidsAffectAlopecia AreataAtopic DermatitisAutoimmuneAutoimmunityAutomobile DrivingBase SequenceBiodistributionBiological ProductsBiological Response ModifiersBiologyCXCL10 geneCXCL11 geneCXCL9 geneCellsCharacteristicsChemical EngineeringChemicalsChemistryClinicClinicalComplexCutaneous Lupus ErythematosusDermatologicDermatologyDevelopmentDiseaseDoseDrug DesignDrug TargetingEngineeringFDA approvedFosteringGene ExpressionGene SilencingGenerationsGenesGoalsHumanHydrophobicityIFNGR1 geneImmune System DiseasesImmune TargetingImmunologic MemoryImmunologyInflammatoryInterferon Type IIInterleukin-15JAK1 geneJAK2 geneJAK3 geneJanus kinaseLeadLiverMentorsMessenger RNAMetabolicModalityMolecularMusNanostructuresNucleic AcidsOutcomePathologyPathway interactionsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhasePopulationProductionPropertyProteinsPublic HealthRNARNA InterferenceRNA deliveryResearchRodentSTAT1 geneSafetySignal PathwaySkinSmall Interfering RNASpecificityStructureTYK2TherapeuticTherapeutic EffectTrainingTreatment outcomeVitiligoWorkbiomaterial compatibilitycell typeclinically relevantcombinatorialdesigndrug discoveryefficacy testingefficacy validationimprovedin vivoinsightinterestkinase inhibitormouse modelnovelnovel drug classpreventprogramsscaffoldside effectskin disorderskin fibrosissmall moleculetargeted treatmenttechnology platformtherapeutic RNAtherapeutic evaluationtreatment strategy
项目摘要
PROJECT SUMMARY
Skin diseases affect nearly one-third of the global population. Current dermatological drugs are inadequate for
many of these diseases, and some have few or no treatments available. There is an urgent need to develop new
dermatological therapies. RNA interference (RNAi)-based therapeutics—e.g., small interfering RNA (siRNA)—
represent a third class of therapeutic modalities, in addition to small molecules and biologics, that enable specific
and sustained mRNA silencing to prevent production of proteins driving disease. With recent advances in nucleic
acid chemistries, five siRNA drugs have been approved by the FDA for treatment of liver-associated diseases.
Key benefits of siRNA drugs include: (a) ease of sequence-based design; (b) high specificity; (c) a well-defined
mechanism of action; and (d) long durability (up to 3-6 months from one dose). These properties of siRNAs allow
rapid drug discovery and durable modulation of disease targets previously considered “undruggable”.
The goal of this proposal is to expand the clinical utility of therapeutic siRNAs for the treatment of skin diseases.
An siRNA that silences expression of the immune mediator, JAK1 (human and mouse), and supports functional
inhibition of JAK1 in vivo, has been identified. Aim 1 (K99 phase) will systematically evaluate the safety and
efficacy of selective JAK1 silencing by therapeutic siRNA in mouse models of autoimmune and inflammatory
skin diseases (i.e., vitiligo, cutaneous lupus erythematosus, and skin fibrosis).
Gene silencing in skin requires efficient delivery of chemically-engineered siRNA to skin cell types expressing
the target gene. Aim 2 (K99 phase) will dissect the skin biodistribution and efficacy profiles of hydrophobically
conjugated siRNAs targeting JAK1 following local and systemic delivery. The R00 phase will expand the scope
of the siRNA delivery platform by determining skin cell biodistribution and efficacy of new siRNA conjugates and
scaffolds, and siRNAs targeting immune mediators in the IFN-γ (i.e., IFNGR1, JAK2, STAT1, and CXCL9/10/11)
and IL15 (i.e., IL15 and IL15RA) pathways, for which lead compounds have already been identified.
Preliminary work has developed a dual-targeting siRNA scaffold supporting simultaneous silencing of two genes
in vivo. Aim 3 (K99 phase) will test the efficacy of modulating two inflammatory targets in the mouse models
mentioned in Aim 1. In the R00 phase, biocompatible click chemistry and nanostructure engineering strategies
will be used to construct programmable unimolecular multi-targeting siRNA scaffolds to potentiate combinatorial
modulation of 3 or more inflammatory targets, a crucial goal for treating skin diseases with complex pathology.
This project will establish an siRNA-based platform for modulating gene expression in the skin, and foster the
PI’s continued scientific and professional training. Research in the mentored K99 phase will be carried out under
the guidance of an esteemed mentor committee, whose expertise range from basic RNA biology to clinical
dermatology. By the R00 phase, the PI will be ready to establish an independent lab focused on developing
novel siRNA therapeutic programs for complex skin diseases.
项目摘要
皮肤病影响着全球近三分之一的人口。目前的皮肤病药物不足以
其中许多疾病,有些几乎没有或根本没有治疗方法。迫切需要开发新的
皮肤病治疗。基于RNA干扰(RNAi)的治疗-例如,小干扰RNA(siRNA)-
代表了第三类治疗方式,除了小分子和生物制剂,
和持续的mRNA沉默以防止产生驱动疾病的蛋白质。随着核酸研究的最新进展,
除了酸化学之外,FDA已经批准了五种siRNA药物用于治疗肝脏相关疾病。
siRNA药物的主要益处包括:(a)易于基于序列的设计;(B)高特异性;(c)明确的靶向分子;(d)特异性靶向分子。
作用机制;和(d)持久性(从一次剂量起长达3-6个月)。siRNA的这些特性使得
快速药物发现和持久调节以前被认为是“不可用药”的疾病靶点。
该提案的目标是扩大治疗性siRNA用于治疗皮肤疾病的临床效用。
沉默免疫介质JAK 1(人和小鼠)表达并支持功能性免疫调节的siRNA
JAK 1的体内抑制。目标1(K99阶段)将系统评价安全性,
在自身免疫和炎症小鼠模型中通过治疗性siRNA选择性沉默JAK 1的功效
皮肤病(即,白癜风、皮肤红斑狼疮和皮肤纤维化)。
皮肤中的基因沉默需要将化学工程siRNA有效递送至表达
目标基因。目的2(K99阶段)将剖析疏水性的皮肤生物分布和功效概况。
在局部和全身递送后靶向JAK 1的缀合siRNA。R 00阶段将扩大范围
通过测定新siRNA缀合物的皮肤细胞生物分布和功效,
支架和靶向IFN-γ中免疫介体的SiRNA(即,IFNGR 1、JAK 2、STAT 1和CXCL 9/10/11)
和IL 15(即,IL 15和IL 15 RA)途径,其先导化合物已经被鉴定。
初步工作已经开发出一种支持同时沉默两个基因的双靶向siRNA支架
in vivo.目的3(K99期)将测试在小鼠模型中调节两种炎症靶标的功效
目标1中提到的。在R 00阶段,生物相容性点击化学和纳米结构工程策略
将用于构建可编程单分子多靶向siRNA支架,以增强组合
调节3个或更多个炎症靶点,这是治疗具有复杂病理学的皮肤疾病的关键目标。
该项目将建立一个基于siRNA的平台,用于调节皮肤中的基因表达,
PI的持续科学和专业培训。K99阶段的研究将在
一个受人尊敬的指导委员会的指导,其专业知识范围从基本的RNA生物学到临床
皮肤科。到R 00阶段,PI将准备建立一个独立的实验室,专注于开发
用于复杂皮肤病的新型siRNA治疗方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qi Tang其他文献
Qi Tang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 11.32万 - 项目类别:
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 11.32万 - 项目类别:
Continuing Grant
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 11.32万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Operating Grants
Metabolomic profiles of responders and non-responders to an omega-3 fatty acids supplementation.
对 omega-3 脂肪酸补充剂有反应和无反应者的代谢组学特征。
- 批准号:
495594 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)